Keywords: Molecular Imaging, Cancer
Motivation: The therapeutic landscape for pancreatic cancer is particularly bleak, there is no truly curative neoadjuvant therapy available in the clinic.
Goal(s): Unfortunately, available imaging does not reliably evaluate pancreatic tumor response to neoadjuvant treatment and underrepresents the extent of the tumor, which leads to suboptimal clinical management. Therefore, we developed a non-invasive MR method for evaluation of treatment response.
Approach: We utilized a molecular MR-based T1w acquisition using a lymphokine targeting contrast agent during novel vaccine therapy.
Results: When tumors responded to therapy, we found significant signal changes that were qualitatively and quantitatively assessed to determine outcomes later.
Impact: By using MR molecular imaging in preclinical PDAC models we can better evaluate novel therapeutic agents and provide more accurate and accessible precision care tools for response prediction.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords